Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-01-31
DOI
10.3389/fimmu.2022.807271
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tryptophan Metabolites at the Crossroad of Immune-Cell Interaction via the Aryl Hydrocarbon Receptor: Implications for Tumor Immunotherapy
- (2021) Marco Gargaro et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer
- (2021) Nuria Kotecki et al. JOURNAL OF IMMUNOTHERAPY
- Current Challenges for IDO2 as Target in Cancer Immunotherapy
- (2021) Giada Mondanelli et al. Frontiers in Immunology
- IDO1 Expression in Ovarian Cancer Induces PD-1 in T Cells via Aryl Hydrocarbon Receptor Activation
- (2021) Adaobi Amobi-McCloud et al. Frontiers in Immunology
- Challenges in targeting the tryptophan metabolism in cancer immunotherapy
- (2021) Julia Schollbach et al. Aging-US
- 3-hydroxy-L-kynurenamine is an immunomodulatory biogenic amine
- (2021) Cristina C. Clement et al. Nature Communications
- Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma
- (2021) Yousef Zakharia et al. Journal for ImmunoTherapy of Cancer
- Off-tumor IDO1 target engagements determine the cancer-immune set point and predict the immunotherapeutic efficacy
- (2021) Lin Xie et al. Journal for ImmunoTherapy of Cancer
- Not Only Immune Escape—The Confusing Role of the TRP Metabolic Pathway in Carcinogenesis
- (2021) Iwona Kwiatkowska et al. Cancers
- A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
- (2021) Julie Westerlin Kjeldsen et al. NATURE MEDICINE
- A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma
- (2020) David A. Reardon et al. INVESTIGATIONAL NEW DRUGS
- Discovery of indoximod prodrugs and characterization of clinical candidate NLG802
- (2020) Sanjeev Kumar et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- A decade of immune-checkpoint inhibitors in cancer therapy
- (2020) Caroline Robert Nature Communications
- Indoximod opposes the immunosuppressive effects mediated by IDO and TDO via modulation of AhR function and activation of mTORC1
- (2020) Erik L. Brincks et al. Oncotarget
- Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1
- (2020) Andrea Botticelli et al. Frontiers in Immunology
- Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
- (2019) Kyung Hae Jung et al. CLINICAL CANCER RESEARCH
- A novel dual inhibitor of IDO and TDO, CMG017, potently suppresses the kynurenine pathway and overcomes resistance to immune checkpoint inhibitors.
- (2019) Chan Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39
- (2019) Maisa C. Takenaka et al. NATURE NEUROSCIENCE
- Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
- (2019) Georgina V Long et al. LANCET ONCOLOGY
- Metabolomic adaptations and correlates of survival to immune checkpoint blockade
- (2019) Haoxin Li et al. Nature Communications
- Tumor-Repopulating Cells Induce PD-1 Expression in CD8 + T Cells by Transferring Kynurenine and AhR Activation
- (2018) Yuying Liu et al. CANCER CELL
- IDO1 in cancer: a Gemini of immune checkpoints
- (2018) Lijie Zhai et al. Cellular & Molecular Immunology
- Regulation of the Immune Response by the Aryl Hydrocarbon Receptor
- (2018) Cristina Gutiérrez-Vázquez et al. IMMUNITY
- Reversal of indoleamine 2,3-dioxygenase–mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme
- (2018) Todd A Triplett et al. NATURE BIOTECHNOLOGY
- Microbiome: Gut microbiota sways response to cancer immunotherapy
- (2018) Ashley York NATURE REVIEWS MICROBIOLOGY
- Targeting the IDO1/TDO2–KYN–AhR Pathway for Cancer Immunotherapy – Challenges and Opportunities
- (2018) Jae Eun Cheong et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Impact of the Gut Microbiota on Intestinal Immunity Mediated by Tryptophan Metabolism
- (2018) Jing Gao et al. Frontiers in Cellular and Infection Microbiology
- Abstract LB-128: The aryl hydrocarbon receptor as driver of cancer immunity
- (2018) David Sherr et al. CANCER RESEARCH
- Abstract 1701: EPL-1410, a novel fused heterocycle based orally active dual inhibitor of IDO1/TDO2, as a potential immune-oncology therapeutic
- (2018) Srinivas Gullapalli et al. CANCER RESEARCH
- Abstract 4719: Small-molecule antagonists of the Aryl Hydrocarbon Receptor (AhR) promote activation of human PBMCs in vitro and demonstrate significant impact on tumor growth and immune modulation in vivo
- (2018) James Joseph et al. CANCER RESEARCH
- A Role for Tryptophan-2,3-dioxygenase in CD8 T Cell Suppression and Evidence of Tryptophan Catabolism in Breast Cancer Patient Plasma
- (2018) Lisa I Greene et al. MOLECULAR CANCER RESEARCH
- Indoximod: An Immunometabolic Adjuvant That Empowers T Cell Activity in Cancer
- (2018) Eric Fox et al. Frontiers in Oncology
- Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis
- (2018) Brian W. Labadie et al. CLINICAL CANCER RESEARCH
- The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy
- (2017) Lieve Brochez et al. EUROPEAN JOURNAL OF CANCER
- A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer
- (2017) Rebecca Kristeleit et al. GYNECOLOGIC ONCOLOGY
- Aryl Hydrocarbon Receptor Controls Monocyte Differentiation into Dendritic Cells versus Macrophages
- (2017) Christel Goudot et al. IMMUNITY
- The crystal structure of the AhRR–ARNT heterodimer reveals the structural basis of the repression of AhR-mediated transcription
- (2017) Shunya Sakurai et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Trace derivatives of kynurenine potently activate the aryl hydrocarbon receptor (AHR)
- (2017) Seung-Hyeon Seok et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Tumor-associated macrophages: from basic research to clinical application
- (2017) Li Yang et al. Journal of Hematology & Oncology
- A Molecular Mechanism To Switch the Aryl Hydrocarbon Receptor from a Transcription Factor to an E3 Ubiquitin Ligase
- (2017) Sandra Luecke-Johansson et al. MOLECULAR AND CELLULAR BIOLOGY
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors activate the aryl hydrocarbon receptor
- (2017) Benjamin J. Moyer et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology
- (2017) Eddy W. Yue et al. ACS Medicinal Chemistry Letters
- Indoximod Combo Triggers Responses in Melanoma
- (2017) Cancer Discovery
- Tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase 1 make separate, tissue-specific contributions to basal and inflammation-induced kynurenine pathway metabolism in mice
- (2016) Paul B. Larkin et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- Abstract 4863: PF-06840003: a highly selective IDO-1 inhibitor that shows good in vivo efficacy in combination with immune checkpoint inhibitors
- (2016) Joseph Tumang et al. CANCER RESEARCH
- Abstract LB-085: RG70099: A novel, highly potent dual IDO1/TDO inhibitor to reverse metabolic suppression of immune cells in the tumor micro-environment
- (2016) Gabor Gyulveszi et al. CANCER RESEARCH
- Regulatory T cells in cancer immunotherapy
- (2016) Atsushi Tanaka et al. CELL RESEARCH
- Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment
- (2016) Stefani Spranger INTERNATIONAL IMMUNOLOGY
- Tryptophan-2,3-dioxygenase is regulated by prostaglandin E2 in malignant glioma via a positive signaling loop involving prostaglandin E receptor-4
- (2016) Katharina Ochs et al. JOURNAL OF NEUROCHEMISTRY
- Constitutive aryl hydrocarbon receptor signaling constrains type I interferon–mediated antiviral innate defense
- (2016) Taisho Yamada et al. NATURE IMMUNOLOGY
- IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance
- (2016) David H. Munn et al. TRENDS IN IMMUNOLOGY
- The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
- (2016) Vinit Kumar et al. TRENDS IN IMMUNOLOGY
- Targeting the Inhibition of Tryptophan 2,3-Dioxygenase (TDO-2) for Cancer Treatment
- (2016) Ahmed F. Abdel-Magid ACS Medicinal Chemistry Letters
- The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells
- (2016) Caroline Jochems et al. Oncotarget
- Tolerogenic IDO+ Dendritic Cells Are Induced by PD-1-Expressing Mast Cells
- (2016) Cecilia Pessoa Rodrigues et al. Frontiers in Immunology
- The stress kinase GCN2 does not mediate suppression of antitumor T cell responses by tryptophan catabolism in experimental melanomas
- (2016) Jana K. Sonner et al. OncoImmunology
- Abstract LB-226: Depletion of kynurenine using an engineered therapeutic enzyme potently inhibits cancer immune checkpoints both as a monotherapy and in combination with anti-PD-1
- (2015) Everett Stone et al. CANCER RESEARCH
- Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy
- (2015) L. Zhai et al. CLINICAL CANCER RESEARCH
- Indoleamine 2,3-dioxygenase depletes tryptophan, activates general control non-derepressible 2 kinase and down-regulates key enzymes involved in fatty acid synthesis in primary human CD4+T cells
- (2015) Theodoros Eleftheriadis et al. IMMUNOLOGY
- Expression profile of the human IDO1 protein, a cancer drug target involved in tumoral immune resistance
- (2015) Nathalie Vigneron et al. OncoImmunology
- Characterization of thein vivoimmune network of IDO, tryptophan metabolism, PD-L1, andCTLA-4in circulating immune cells in melanoma
- (2015) I Chevolet et al. OncoImmunology
- The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment
- (2015) M. D. Sharma et al. Science Advances
- Improved anti-tumor immunity and efficacy upon combination of the IDO1 inhibitor GDC-0919 with anti-PD-l1 blockade versus anti-PD-l1 alone in preclinical tumor models
- (2015) Jessica Spahn et al. Journal for ImmunoTherapy of Cancer
- Abstract 5023: Synergistic antitumor effects of combinatorial immune checkpoint inhibition with anti-PD-1/PD-L antibodies and the IDO pathway inhibitors NLG-919 and indoximod in the context of active immunotherapy
- (2015) Mario R. Mautino et al. CANCER RESEARCH
- Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR
- (2015) Ulrike M. Litzenburger et al. Oncotarget
- Keeping the eIF2 alpha kinase Gcn2 in check
- (2014) Beatriz A. Castilho et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer
- (2014) George C. Prendergast et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Abstract 491: NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy.
- (2014) Mario R. Mautino et al. CANCER RESEARCH
- Activation of the aryl hydrocarbon receptor affects activation and function of human monocyte-derived dendritic cells
- (2014) C. Wang et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors
- (2014) D. A. Wainwright et al. CLINICAL CANCER RESEARCH
- The Aryl Hydrocarbon Receptor Promotes IL-10 Production by NK Cells
- (2014) S. Wagage et al. JOURNAL OF IMMUNOLOGY
- Ligand Promiscuity of Aryl Hydrocarbon Receptor Agonists and Antagonists Revealed by Site-Directed Mutagenesis
- (2014) A. A. Soshilov et al. MOLECULAR AND CELLULAR BIOLOGY
- Aryl hydrocarbon receptor control of a disease tolerance defence pathway
- (2014) Alban Bessede et al. NATURE
- Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues
- (2014) I. Theate et al. Cancer Immunology Research
- Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment
- (2014) Stefani Spranger et al. Journal for ImmunoTherapy of Cancer
- Cross-talk between Aryl Hydrocarbon Receptor and the Inflammatory Response
- (2013) Christoph F. A. Vogel et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
- (2013) Rikke B. Holmgaard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The New Aryl Hydrocarbon Receptor Antagonist E/Z-2-Benzylindene-5,6-Dimethoxy-3,3-Dimethylindan-1-One Protects against UVB-Induced Signal Transduction
- (2013) Julia Tigges et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Modulation of natural killer cell antitumor activity by the aryl hydrocarbon receptor
- (2013) J. H. Shin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
- (2013) S. Spranger et al. Science Translational Medicine
- Tryptophan Catabolism in Cancer: Beyond IDO and Tryptophan Depletion
- (2012) M. Platten et al. CANCER RESEARCH
- Nanoparticle-mediated codelivery of myelin antigen and a tolerogenic small molecule suppresses experimental autoimmune encephalomyelitis
- (2012) A. Yeste et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase
- (2012) L. Pilotte et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Indoleamine 2,3 dioxygenase and metabolic control of immune responses
- (2012) David H. Munn et al. TRENDS IN IMMUNOLOGY
- IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development
- (2012) Courtney Smith et al. Cancer Discovery
- IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan
- (2012) Richard Metz et al. OncoImmunology
- Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives
- (2011) J. Godin-Ethier et al. CLINICAL CANCER RESEARCH
- An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
- (2011) Christiane A. Opitz et al. NATURE
- IDO: more than an enzyme
- (2011) WanJun Chen NATURE IMMUNOLOGY
- Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells
- (2011) Maria T Pallotta et al. NATURE IMMUNOLOGY
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Activation of the Aryl Hydrocarbon Receptor by TCDD Inhibits Mammary Tumor Metastasis in a Syngeneic Mouse Model of Breast Cancer
- (2011) Tao Wang et al. TOXICOLOGICAL SCIENCES
- Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity
- (2010) X. Liu et al. BLOOD
- An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells
- (2010) J. D. Mezrich et al. JOURNAL OF IMMUNOLOGY
- Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors
- (2010) H. K. Koblish et al. MOLECULAR CANCER THERAPEUTICS
- The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27
- (2010) Lionel Apetoh et al. NATURE IMMUNOLOGY
- Breast Cancer Stem-Like Cells Are Inhibited by a Non-Toxic Aryl Hydrocarbon Receptor Agonist
- (2010) Gérald J. Prud'homme et al. PLoS One
- Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism
- (2010) N. T. Nguyen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis
- (2010) F. J. Quintana et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Kynurenic Acid Is a Potent Endogenous Aryl Hydrocarbon Receptor Ligand that Synergistically Induces Interleukin-6 in the Presence of Inflammatory Signaling
- (2010) Brett C. DiNatale et al. TOXICOLOGICAL SCIENCES
- Aryl hydrocarbon receptor in combination with Stat1 regulates LPS-induced inflammatory responses
- (2009) Akihiro Kimura et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Activation of the Aryl-Hydrocarbon Receptor Inhibits Invasive and Metastatic Features of Human Breast Cancer Cells and Promotes Breast Cancer Cell Differentiation
- (2009) Julie M. Hall et al. MOLECULAR ENDOCRINOLOGY
- Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor
- (2008) Francisco J. Quintana et al. NATURE
- The Search for Endogenous Activators of the Aryl Hydrocarbon Receptor
- (2007) Linh P. Nguyen et al. CHEMICAL RESEARCH IN TOXICOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started